Stock On Watch: Could Ariad Pharmaceuticals, Inc. Skyrocket Even More? The Stock Just Made 52-Week High

Stock On Watch: Could Ariad Pharmaceuticals, Inc. Skyrocket Even More? The Stock Just Made 52 Week High

The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) hit a new 52-week high and has $14.74 target or 6.00% above today’s $13.91 share price. The 7 months bullish chart indicates low risk for the $2.61 billion company. The 1-year high was reported on Nov, 29 by Barchart.com. If the $14.74 price target is reached, the company will be worth $156.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 5.85 million shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 88.97% since April 26, 2016 and is uptrending. It has outperformed by 83.71% the S&P500.

Analysts await Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) to report earnings on February, 28. They expect $-0.17 EPS, up 46.88% or $0.15 from last year’s $-0.32 per share. After $-0.14 actual EPS reported by Ariad Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage

Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. $22 is the highest target while $5 is the lowest. The $13.19 average target is -5.18% below today’s ($13.91) stock price. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Wednesday, March 9, the company rating was maintained by JMP Securities. JMP Securities downgraded the stock to “Mkt Perform” rating in Tuesday, October 25 report. As per Tuesday, January 19, the company rating was initiated by Barclays Capital. The firm earned “Underweight” rating on Monday, October 24 by JP Morgan. Barclays Capital maintained the stock with “Underweight” rating in Wednesday, May 11 report. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Buy” rating by SunTrust on Wednesday, October 5. The rating was initiated by Deutsche Bank with “Hold” on Thursday, November 3. The rating was maintained by JP Morgan with “Neutral” on Friday, August 7. The rating was maintained by Barclays Capital with “Underweight” on Friday, July 29. The firm has “Buy” rating given on Wednesday, October 5 by Suntrust Robinson.

According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”

Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.16, from 1.4 in 2016Q1. The ratio dived, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Sei Invs has 57,941 shares for 0% of their US portfolio. Invesco accumulated 0% or 857,630 shares. Royal Bank & Trust Of Canada last reported 64,190 shares in the company. Pinnacle Assoc Ltd accumulated 0.01% or 33,770 shares. The Illinois-based First Tru L P has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Fifth Third Bank & Trust last reported 1,500 shares in the company. Blackrock Institutional Tru Na has 4.55M shares for 0.01% of their US portfolio. The Georgia-based Voya Inv Mngmt Limited Liability Corporation has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Panagora Asset Mngmt Incorporated has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Employees Retirement Association Of Colorado accumulated 49,455 shares or 0% of the stock. Sarissa Cap Mngmt Ltd Partnership accumulated 26.95% or 12.85 million shares. California Public Employees Retirement Sys, a California-based fund reported 352,900 shares. Canada Pension Plan Inv Board holds 0% or 20,900 shares in its portfolio. Js Mngmt Llc accumulated 1.15% or 807,700 shares. Old Mutual Glob Investors (Uk) accumulated 0.21% or 1.52 million shares.

Insider Transactions: Since June 10, 2016, the stock had 0 buys, and 10 insider sales for $3.87 million net activity. 20,000 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $268,536 were sold by CLACKSON TIMOTHY P. Radaelli Massimo sold $896,135 worth of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Friday, June 10. Shares for $626,039 were sold by LAVIDAS ATHANESE on Monday, June 13.

More news for Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) were recently published by: Fool.com, which released: “3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results” on November 07, 2016. Schaeffersresearch.com‘s article titled: “Buzz Stocks: Ariad Pharmaceuticals, Inc., Tiffany & Co., and TiVo Corp” and published on November 29, 2016 is yet another important article.

ARIA Company Profile

ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment